Cancer History Avoids the Increase of Senescence Markers in Peripheral Cells of Amnestic Mild Cognitive Impaired Patients

• Published in: International journal of molecular sciences Vol. 24; no. 8; p. 7364
• Main Authors: SanMartín, Carol D., Salech, Felipe, Ponce, Daniela Paz, Concha-Cerda, Jorge, Romero-Hernández, Esteban, Liabeuf, Gianella, Rogers, Nicole K., Murgas, Paola, Bruna, Bárbara, More, Jamileth, Behrens, María I.
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 17.04.2023; MDPI
• Subjects: Advertising executives; Alzheimer Disease - genetics; Alzheimer's disease; Cancer; Cell death; Cognition; Cognitive Dysfunction - genetics; Comparative analysis; Development and progression; Epidemiology; Humans; Interleukin-6; Interleukin-8; Leukocytes, Mononuclear; Medical research; Medicine, Experimental; Neoplasms; Neuropsychological Tests; RNA; RNA, Messenger; Tumor proteins; United Kingdom; Chile; Massachusetts; Germany; Alzheimer’s Disease (AD); peripheral blood mononuclear cells (PBMCs); cellular senescence; aging; amnestic mild cognitive impairment (aMCI); cancer history
• ISSN: 1422-0067; 1422-0067
• DOI: 10.3390/ijms24087364

Epidemiological studies show that having a history of cancer protects from the development of Alzheimer’s Disease (AD), and vice versa, AD protects from cancer. The mechanism of this mutual protection is unknown. We have reported that the peripheral blood mononuclear cells (PBMC) of amnestic cognitive impairment (aMCI) and Alzheimer’s Disease (AD) patients have increased susceptibility to oxidative cell death compared to control subjects, and from the opposite standpoint a cancer history is associated with increased resistance to oxidative stress cell death in PBMCs, even in those subjects who have cancer history and aMCI (Ca + aMCI). Cellular senescence is a regulator of susceptibility to cell death and has been related to the pathophysiology of AD and cancer. Recently, we showed that cellular senescence markers can be tracked in PBMCs of aMCI patients, so we here investigated whether these senescence markers are dependent on having a history of cancer. Senescence-associated βeta-galactosidase (SA-β-Gal) activity, G0-G1 phase cell-cycle arrest, p16 and p53 were analyzed by flow cytometry; phosphorylated H2A histone family member X (γH2AX) by immunofluorescence; IL-6 and IL-8 mRNA by qPCR; and plasmatic levels by ELISA. Senescence markers that were elevated in PBMCs of aMCI patients, such as SA-β-Gal, Go-G1 arrested cells, IL-6 and IL-8 mRNA expression, and IL-8 plasmatic levels, were decreased in PBMCs of Ca + aMCI patients to levels similar to those of controls or of cancer survivors without cognitive impairment, suggesting that cancer in the past leaves a fingerprint that can be peripherally traceable in PBMC samples. These results support the hypothesis that the senescence process might be involved in the inverse association between cancer and AD.